Martin Chandler

Martin Chandler has worked in the biotechnology industry since 1992. Theirwork experience includes an Internship at Dow Chemical in 1992, where they designed and tested a mini-plant scale vapor-phase catalytic reactor. In 1993, they were an Intern at Genentech, where they screened UF membranes for flux, susceptibility to fouling, and retentivity. In 1994, they were an Intern at Dupont Merck. In 1995, they were a Graduate Student at MIT Chemical Engineering Practice School. From 1996 to 2011, they worked at Merck as a Sr. Research Biochemical Engineer. From 2011 to 2013, they were a Purification Scientist II at MedImmune. From 2013 to 2016, they were a Senior Process Scientist at Sutro Biopharma, Inc., where they performed lab-scale experiments for initial proof-of-concept studies, stability studies, and process optimization for freeze-drying E. coli-derived extract. From 2016 to 2019, they were the Associate Director of Biologics and Head of Downstream Development at Nektar Therapeutics. Since 2019, they have been the Director of Process Development at Maverick Therapeutics. Currently, they are the Senior Director of Process Development and Manufacturing at Werewolf Therapeutics.

Martin Chandler obtained their Bachelor of Science in Chemical Engineering and Chemistry from the University of California, Berkeley between 1989 and 1994. Martin then went on to get their Master of Science in Chemical Engineering from the Massachusetts Institute of Technology between 1994 and 1996. Finally, they earned their Doctor of Philosophy in Chemical Engineering from Penn State University between 2002 and 2005.